<DOC>
	<DOCNO>NCT00534352</DOCNO>
	<brief_summary>The purpose study determine pharmacokinetic profile TMC125 400mg tenofovir DF/emtricitabine FDC ( fix dose combination ) 300/200mg dosed daily without darunavir/ritonavir 800/100 mg daily HIV-1 infect , antiretroviral ( ARV ) na√É-ve patient ( patient never receive ARV treatment ) .</brief_summary>
	<brief_title>A Study Evaluate Pharmacokinetic Profile ( How Body Absorbs , Distributes , Metabolizes Eliminates Drug ) TMC125 Plus Tenofovir/Emtricitabine Once Daily With Without Darunavir/r Once Daily Antiretroviral ( ARV ) Naive HIV-1 Patients ( Patients Have Never Received ARV Treatment ) .</brief_title>
	<detailed_description>This multi-center , open-label ( doctor patient know drug give ) , Phase IIa clinical trial evaluate pharmacokinetic ( PK ) profile , safety tolerability TMC125 dose daily tenofovir/emtricitabine without darunavir/ritonavir antiretroviral naive HIV-1 infect patient . There optional open-label extension phase evaluate effectiveness , safety tolerability continue tenofovir/emtricitabine darunavir/ritonavir dose daily 48 week . This study conduct United States 5 site 20 patient initially receive TMC125 400mg tenofovir DF/emtricitabine FDC 300/200 mg dose daily 14 day . On Day 15 , blood sample obtain intensive TMC125 pharmacokinetic ( PK ) value fast lipid ( check total cholesterol , direct LDL , HDL , triglyceride ) follow 10 hour fast ( eat ) assess . Patients add darunavir / ritonavir 800/100 mg day regimen Days 15 - 29 . On Day 29 intensive PK sample TMC125 , darunavir ritonavir perform fasting lipid evaluate . On Day 29 , patient discontinue TMC125 continue darunavir/ritonavir 800/100 mg tenofovir DF/emtricitabine FDC 300/200 mg dose daily . On Day 43 , fast lipid assess . At point , patient may enter optional open-label extension phase study continue treatment darunavir/ritonavir 800mg/100 mg tenofovir DF/emtricitabine FDC 300/200mg dose daily 48 total week treatment . The study consist total 8 visit include 2 intensive PK visit . Within 4 week Screening Visit , study site receive data determine patient 's eligibility study . The Baseline Visit ( Day 1 ) follow study visit Day 8 . An intensive PK visit occur Day 15 . After modification therapy Day 15 , study visit occur Day 22 . A second intensive PK visit occur Day 29 . On Day 43 study visit occur point study therapy discontinue unless patient elect continue optional open label extension phase study . Patients elect continue open-label extension 4 additional study visit Week 12 , 24 , 36 48 . All patient ask return 4-week follow-up visit completion study treatment . During treatment period , patient see regular visit investigator assess patient 's medical condition , Adverse Events study drug compliance . Laboratory evaluation effectiveness safety do regular visit well blood pressure monitoring . All patient receive TMC125 400 mg orally ( mouth ) daily . Tenofovir DF 300mg/emtricitabine 200mg dosed daily orally fix dose combination . Darunavir/ritonavir dose 800/100 mg orally daily . All dos administer follow meal .</detailed_description>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Etravirine</mesh_term>
	<criteria>Documented HIV1 infection Naive antiretroviral therapy ( never receive antiretroviral therapy prior study ) In opinion investigator , indication antiretroviral therapy Able comply protocol requirement No previous current use antiretroviral medication ( ARVs ) treatment HIV infection hepatitis B/C infection antiHIV activity No evidence antiretroviral resistance current past resistance assay No chronic hepatitis B and/or C coinfection No grade 3 4 laboratory abnormality define National Institute Allergy Infectious Diseases Division Acquired Immunodeficiency Syndrome ( DAIDS ) grading table , calculate creatinine clearance ( CLCr ) &lt; 50 mL/min . No known diabetes mellitus hyperlipidemia require lipidlowering therapy No acute viral hepatitis include , limit A , B , C .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>HIV</keyword>
	<keyword>AIDS</keyword>
	<keyword>Immunodeficiency Virus , Human</keyword>
	<keyword>PREZISTA</keyword>
	<keyword>darunavir</keyword>
	<keyword>TMC114</keyword>
	<keyword>TMC125</keyword>
	<keyword>Protease Inhibitor</keyword>
	<keyword>Non-Nucleoside Reverse Transcriptase Inhibitor</keyword>
	<keyword>Truvada</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>